comparemela.com

Latest Breaking News On - Rochester dermatologic surgery - Page 1 : comparemela.com

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients.

New yorkUnited statesCastle biosciencesSherrif ibrahimAmerican joint committee on cancer staging manualAmerican college of mohs surgeryNational comprehensive cancer networkCastle biosciences incAmerican collegeMohs surgeryAnnual meetingRochester dermatologic surgeryPresenting authorSun ballroomSheraton phoenix downtownAmerican joint committee

Recently Published Data Confirm DecisionDx-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors

13.01.2022 - Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced the publication of clinical performance study data demonstrating that DecisionDx-SCC . Seite 1

New yorkUnited statesUniversity of rochesterSherrif ibrahimCastle biosciences incCastle biosciencesMetastatic risk assessmentCutaneous squamous cell carcinomaGene expression profile testRochester dermatologic surgeryRochester medical center

vimarsana © 2020. All Rights Reserved.